This was a non-interventional retrospective study. Data from patients who were diagnosed with myelofibrosis (MF) (primary MF, post-polycythemia vera MF \& post-essential thrombocythemia MF) and treated with ruxolitinib for at least 3 months collectively were collected. The baseline visit was the visit that the patient started ruxolitinib treatment. Data was collected between January 01, 2015 and December 31, 2022. The main baseline clinical and laboratory data of the cohort with at least 3 months of ruxolitinib treatment was documented in order to identify real life patient data in Turkey. All the data was transferred to a clinical report form (CRF), then to the Statistical Package for the Social Sciences (SPSS) software in an anonymous fashion. The source documents were secured for quality control of the data. The quality control of the data was controlled by an unbiased data entry coordinator.
Study Type
OBSERVATIONAL
Enrollment
355
Novartis
East Hanover, New Jersey, United States
Age
Time frame: Baseline
Number of Patients by Gender
Time frame: Baseline
Number of Patients by Clinical Characteristic Category
Clinical characteristics included: * Janus Kinase (JAK) mutation (yes/no) * MF-relevant type of mutation * MF Type * Cytogenic risk assessment (favorable/unfavorable karyotype)
Time frame: Baseline
Time From Diagnosis to Initiation of Ruxolitinib
Time frame: Baseline
Number of Patients by DIPSS+ Risk Stratification
DIPSS+ is a prognostic scoring system used to assign MF patients into 1 of 4 risk categories based on the 8 risk factors: age, hemoglobin level, leukocyte count, percentage of circulating blast cells, presence of constitutional symptoms, platelet count, need for red blood cell transfusion, and unfavorable karyotype. The 4 risk categories are as follows: * Low risk (0 points) * Intermediate-1 risk (1 point) * Intermediate-2 risk (2-3 points) * High risk (4-6 points)
Time frame: Baseline, Month 12
Percentage of Patients With Blood Transfusions
Time frame: Baseline, Month 3, 6, and 12
Percentage of Patients With Splenomegaly
Time frame: Baseline, Month 3, 6, and 12
Change From Baseline in Percentage of Patients With Splenomegaly
Time frame: Baseline, Month 12
Percentage of Patients Categorized by Spleen Size
Spleen size was categorized as follows: * 20 centimeters (cm) or smaller * Bigger than 20 cm
Time frame: Baseline, Month 3, 6, and 12
Hemoglobin Levels
Time frame: Baseline, Month 3, 6, and 12
Hematocrit Levels
Time frame: Baseline, Month 3, 6, and 12
White Blood Cell (Leukocyte) Count
Time frame: Baseline, Month 3, 6, and 12
Platelet Count
Time frame: Baseline, Month 3, 6, and 12
Lactate Dehydrogenase (LDH) Levels
Time frame: Baseline, Month 3, 6, and 12
Number of Patients With Hematological and Non-hematological Adverse Events
Time frame: Up to 12 months
Percentage of Patients With Anemia and Thrombocytopenia
Time frame: Baseline, Month 3, 6, and 12
Percentage of Patients With Treatment Adjustments due to Anemia and Thrombocytopenia
Treatment adjustments included dose modification, treatment interruption, and treatment discontinuation.
Time frame: Month 3, 6, and 12
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.